Alzheimer'
Conditions
Interventions
1, intravenous injection of 370MBq dose of [11C]BU99008 2, intravenous injection of 370MBq dose of[11C]DPA713 3, intravenous injection of 185MBq of [18F]BCPP-EF
Sponsors
Hamamatsu University School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Demnetiing disease patients who met the clinical criteria of the MCI, AD, DLB, PD, FTD, PSP, CBD, MSA, high cortical dysfunction. Healthy subjects whose ADL is normal. All participants who are able to scan PET imaging.
Exclusion criteria
Exclusion criteria: 1, Pregnant, possibly pregnant or lactating women 2, Subjects with claustrophobia 3, patient who had the illness which influence the results of PET study 4, patient who was medicated the drugs which influence the results of PET study 5, Patient with DM whose BS was more than 240mg/dL 6, Subjects who are considered to be inappropriate for participation by the doctors with responsibilities in this study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| quantitative analysis of the distribution of the [11C]BU99008 | — |
Secondary
| Measure | Time frame |
|---|---|
| correlation of reactive astrocyte with cognitive decline, activated microglia, and mitochondrial dysfunction | — |
Countries
Japan
Contacts
Public ContactTatsuhiro Terada
Hamamatsu University School of Medicine HAMAMATSU BioPhotonics Innovation Laboratory, Institute of Photonics Medicine
Outcome results
None listed